Substance Abuse in Adolescents and Young Adults : A Manual for Pediatric and Primary Care Clinicians.
Health is a key component of human development, growth and quality of life. The Health, Medicine and Human Development book series aim to provide a public forum for book publications from a multidisciplinary group of researchers, practitioners and clinicians for an international professional forum i...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , |
| Format: | eBook |
| Language: | English |
| Published: |
Berlin/Boston :
De Gruyter, Inc.,
2013.
|
| Edition: | 1st ed. |
| Series: | Health, Medicine and Human Development Ser.
|
| Subjects: | |
| Online Access: | Click to View |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 12024nam a22005773i 4500 | ||
|---|---|---|---|
| 001 | EBC1209368 | ||
| 003 | MiAaPQ | ||
| 005 | 20230417083402.0 | ||
| 006 | m o d | | ||
| 007 | cr cnu|||||||| | ||
| 008 | 230417s2013 xx o ||||0 eng d | ||
| 020 | |a 9783110311389 |q (electronic bk.) | ||
| 020 | |z 9783110313017 | ||
| 035 | |a (MiAaPQ)EBC1209368 | ||
| 035 | |a (Au-PeEL)EBL1209368 | ||
| 035 | |a (CaPaEBR)ebr10811306 | ||
| 035 | |a (CaONFJC)MIL540439 | ||
| 035 | |a (OCoLC)862809666 | ||
| 040 | |a MiAaPQ |b eng |e rda |e pn |c MiAaPQ |d MiAaPQ | ||
| 050 | 4 | |a RJ506.D78.S83 2013eb | |
| 082 | 0 | |a 616.8600835 | |
| 100 | 1 | |a Greydanus, Donald E. | |
| 245 | 1 | 0 | |a Substance Abuse in Adolescents and Young Adults : |b A Manual for Pediatric and Primary Care Clinicians. |
| 250 | |a 1st ed. | ||
| 264 | 1 | |a Berlin/Boston : |b De Gruyter, Inc., |c 2013. | |
| 264 | 4 | |c ©2013. | |
| 300 | |a 1 online resource (432 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Health, Medicine and Human Development Ser. | |
| 505 | 0 | |a Intro -- Author Index -- Foreword -- Abbreviations -- 1 Introduction: Substance abuse in adolescents and young adults -- Section I: Etiology and diagnosis -- 2 Neurobiology of substance use disorders -- 2.1 Introduction -- 2.2 General concepts -- 2.2.1 Dopamine -- 2.2.2 Serotonin and norepinephrine -- 2.2.3 GABA -- 2.3 Neuropharmacology of specific drugs -- 2.3.1 Stimulants -- 2.3.2 Alcohol -- 2.3.3 Opioids -- 2.3.4 Nicotine/tobacco -- 2.3.5 Cannabinoids -- 2.4 Summary -- 3 Genetic influences on substance abuse disorders -- 3.1 Introduction -- 3.2 Limitations -- 3.3 Gene classes -- 3.4 Specific addictions -- 3.4.1 Alcohol -- 3.4.2 Cannabis -- 3.4.3 Tobacco -- 3.4.4 Others -- 3.5 Epigenetic effects -- 3.6 Complex diseases -- 3.7 Conclusion -- 4 Essential diagnostic considerations -- 4.1 Introduction -- 4.2 Review of the literature -- 4.3 Epidemiology -- 4.4 Empirical studies of assessment instruments -- 4.5 Comorbidity -- 4.6 Assessment -- 4.7 Screening -- 4.8 Diagnosis -- 4.9 Biochemical testing -- 4.10 Discussion -- Section II: Treatment -- 5 Psychosocial treatments for substance use disorders -- 5.1 Introduction -- 5.2 Motivational treatments -- 5.2.1 Precontemplation stage -- 5.2.2 Contemplation stage -- 5.2.3 Preparation stage -- 5.2.4 Action stage -- 5.2.5 Maintenance stage -- 5.2.6 Contemplation of relapse -- 5.3 CM and community reinforcement approaches (CRAs) -- 5.3.1 CM -- 5.3.2 CRA -- 5.4 Cognitive behavioral approaches -- 5.4.1 Functional analysis -- 5.4.2 Drug refusal skills -- 5.4.3 RP -- 5.5 Family interventions -- 5.5.1 Multidimensional family therapy (MDFT) -- 5.6 Conclusion -- 6 General pharmacotherapy principles -- 6.1 Introduction -- 6.2 Evaluation for pharmacotherapy -- 6.3 When is pharmacotherapy appropriate? -- 6.4 Conclusion -- 7 Use of pharmacological agents for smoking cessation -- 7.1 Introduction -- 7.2 Epidemiology. | |
| 505 | 8 | |a 7.3 Chemistry and pharmacology -- 7.4 Effects on health -- 7.5 Behavioral approaches to smoking cessation -- 7.6 Pharmacological agents -- 7.6.1 Varenicline -- 7.6.2 Bupropion SR -- 7.6.3 Nicotine replacement therapies -- 7.6.4 Second-line medications -- 7.6.5 Vaccine -- 7.6.6 E-cigarettes -- 7.7 Conclusion -- 8 Marijuana: Current concepts and conundrums -- 8.1 Introduction -- 8.1.1 Cannabis sativa plant -- 8.1.2 Prevalence -- 8.1.3 Cannabis lab testing -- 8.2 Medical adverse effects -- 8.2.1 Cannabis hyperemesis -- 8.2.2 Dental effects of cannabis -- 8.2.3 Pulmonary effects -- 8.2.4 Cannabis and cancer -- 8.2.5 Cardiovascular effects -- 8.2.6 Motor vehicle accidents -- 8.2.7 Sports doping -- 8.2.8 Adverse effects: Psychiatric -- 8.2.9 Management -- 8.2.10 Pharmacological therapies -- 8.2.11 Cannabis intoxication -- 8.2.12 Cannabis withdrawal -- 8.3 Cannabis-associated psychosis -- 8.3.1 Cannabis dependence -- 8.4 Summary -- 9 Primary care management of alcohol use disorders of adolescents and young adults -- 9.1 Introduction -- 9.2 Epidemiology: Drinking patterns and beverage preferences -- 9.2.1 Drinking patterns -- 9.2.2 Drinking preferences -- 9.3 Confidentiality in primary care -- 9.4 Screening in primary care -- 9.4.1 Screening -- 9.4.2 Screening tools -- 9.5 Assessment of risk -- 9.5.1 Screening the college student -- 9.6 BIs for the primary care office -- 9.7 MI -- 9.8 A clinical vignette -- 9.9 Specific BIs for college students -- 9.10 Sedative/hypnotics -- 9.10.1 Epidemiology -- 9.10.2 Associated problems -- 9.11 Conclusions -- 10 Opioids and prescription drugs -- 10.1 Introduction -- 10.2 Prescription drugs -- 10.3 Analgesics -- 10.4 Tranquilizers -- 10.5 Stimulants -- 10.6 Others -- 10.7 OTC drugs -- 10.8 DXM -- 10.9 Antihistamines -- 10.10 Illicit opioids -- 10.11 Conclusion -- 11 Illicit stimulant abuse in adolescents and young adults. | |
| 505 | 8 | |a 11.1 Introduction -- 11.2 History of cocaine and methamphetamine -- 11.3 Epidemiology -- 11.4 Risk factors and comorbidity -- 11.5 Pharmacology and pathophysiology -- 11.6 Clinical manifestations of intoxication, overdose, and withdrawal -- 11.7 Identification of warning signs -- 11.8 Problem use (abuse and dependence) -- 11.9 Treatment of illicit stimulant abuse and dependence -- 11.10 Biological treatments -- 11.11 Behavioral treatments -- 11.12 Clinical management of co-occurring ADHD and stimulant use disorders -- 11.13 Summary -- 12 Date rape drugs and hallucinogens -- 12.1 Introduction -- 12.2 Hallucinogens -- 12.2.1 LSD -- 12.2.2 Mescaline (2,3,4-trimethoxy-phenethylamine) -- 12.2.3 Psilocybin (and closely related psilocyn) -- 12.2.4 Salvia divinorum -- 12.2.5 PCP -- 12.2.6 Ketamine -- 12.2.7 MDMA -- 12.2.8 Methamphetamine -- 12.3 Date rape drugs -- 12.3.1 GHB -- 12.3.2 Flunitrazepam (Rohypnol) -- 12.4 Epidemiology -- 12.5 Diagnosis -- 12.6 Management principles -- 12.7 Conclusions -- 13 The role of the pediatrician and primary care clinician -- 13.1 Introduction -- 13.2 Screening and assessment -- 13.3 Confidentiality and consent -- 13.4 Safety -- 13.5 Screening tools and algorithm in adolescents -- 13.6 Screening tools in young adults -- 13.7 Summary -- 13.8 Brief intervention -- 13.9 Referral to treatment and the primary care clinician's role intreatment -- 13.10 Conclusions -- Section III: Special populations -- 14 Substance use disorders in adolescents and young adults: Comorbidity and treatment -- 14.1 Introduction -- 14.2 Common comorbid psychiatric conditions -- 14.2.1 Clinical samples -- 14.3 General principles of assessment and diagnosis -- 14.4 General principles of treatment -- 14.4.1 ADHD -- 14.4.2 Depressive disorders -- 14.4.3 BPD -- 14.4.4 Psychotic disorders -- 14.4.5 Anxiety disorders. | |
| 505 | 8 | |a 14.4.6 Treatment recommendations and prognosis -- 15 Adolescent girls and substance abuse: Recent trends, risk factors, and consequences -- 15.1 Introduction -- 15.2 Gender differences in substance abuse -- 15.3 Risk factors for substance abuse in female adolescents -- 15.3.1 Puberty status and timing -- 15.4 Hormonal changes and emotional reactivity -- 15.5 Childhood sexual abuse -- 15.6 Consequences of substance abuse in female adolescents -- 15.7 Substance abuse and sexual activity -- 15.8 Substance abuse and unwanted pregnancy -- 15.9 Substance abuse and psychiatric disorders -- 15.10 Perinatal mood disorders -- 15.11 Spectrum of perinatal mood disorders -- 15.11.1 Postpartum blues -- 15.11.2 Postpartum psychosis -- 15.11.3 Postpartum depression (PPD) -- 15.12 Substance abuse and suicide risk in young girls -- 15.13 Impact of substance abuse on adolescent mother and offspring -- 15.14 Substance abuse and unintentional injuries -- 15.15 Prevention and treatment strategies specific for adolescent girls -- 15.15.1 Self-in-relation theory of women development -- 15.15.2 Social-structural model -- 15.15.3 Theory of gender and power -- 15.16 Treatment of comorbid psychiatric illness -- 15.17 Treatment of substance abuse in pregnant adolescents -- 15.18 Future of substance abuse treatment -- 15.19 Conclusions -- 16 Prescription stimulant and other substance abuse in college students -- 16.1 Introduction -- 16.2 Alcohol -- 16.2.1 Prevalence and demographic features -- 16.2.2 Consequences -- 16.2.3 New methods of ingestion -- 16.2.4 Prevention and treatment -- 16.3 Nicotine -- 16.3.1 Treatment -- 16.4 Marijuana -- 16.4.1 Consequences -- 16.4.2 Association with other conditions and implications for prevention and treatment -- 16.5 Cocaine -- 16.6 Prescribed stimulants -- 16.6.1 Associations/risk factors for misuse and diversion. | |
| 505 | 8 | |a 16.6.2 Prevention and treatment -- 16.7 Conclusions -- 17 Sports doping by adolescent athletes -- 17.1 Introduction -- 17.2 Protection for consumers -- 17.3 Definitions -- 17.4 Anabolic agents -- 17.4.1 Epidemiology -- 17.4.2 Effects -- 17.4.3 Adverse effects -- 17.4.4 Use of additional or concomitant doping agents with AAS -- 17.4.5 Prevention -- 17.5 Dihydroepiandrostenedione (DHEA) -- 17.6 Androstenedione -- 17.7 hGH -- 17.8 Gamma hydroxybutyrate (GHB) -- 17.9 Clenbuterol -- 17.10 Creatine -- 17.11 Stimulants -- 17.11.1 Ephedrine -- 17.11.2 Caffeine -- 17.12 Blood doping and erythropoietin (EPO) -- 17.13 Miscellaneous sports-doping agents -- 17.14 Conclusions -- 18 Prenatal drug exposure: Maternal and fetal issues -- 18.1 Introduction -- 18.2 Screening and diagnosis -- 18.3 Alcohol -- 18.4 Tobacco -- 18.5 Marijuana -- 18.6 Opioids -- 18.7 Cocaine -- 18.8 Methamphetamine/amphetamines -- 18.9 Benzodiazepines -- 18.10 Inhalants -- 18.11 Conclusions -- Section IV: New challenges and policy -- 19 New drugs of abuse in the 21st century -- 19.1 Introduction -- 19.2 Cannabinoids -- 19.3 Stimulants -- 19.4 Dissociative anesthetics -- 19.5 Hallucinogens -- 19.6 Conclusions -- 20 Estimating the societal burden of substance abuse: Advantages and limitations of current methodologies -- 20.1 Introduction -- 20.2 The cost-of-illness (COI) approach -- 20.3 What components drive the costs of abuse for each substance? -- 20.3.1 Cigarette smoking -- 20.3.2 Alcohol -- 20.3.3 Illegal drugs -- 20.4 Variations and controversies -- 20.4.1 Revisiting costs of crime -- 20.4.2 Including domestic violence, child abuse, and neglect -- 20.4.3 Including intangible costs of dependence and death -- 20.4.4 Cost offsets -- 20.4.5 Imperfect rationality -- 20.5 Conclusions -- 21 The pros and cons of legalization -- 21.1 Introduction -- 21.1.1 Difficult policy choices. | |
| 505 | 8 | |a 21.2 Current policy: Prohibition. | |
| 520 | |a Health is a key component of human development, growth and quality of life. The Health, Medicine and Human Development book series aim to provide a public forum for book publications from a multidisciplinary group of researchers, practitioners and clinicians for an international professional forum interested in the broad spectrum of health, medicine and human development. We welcome research on a wide variety of substantive areas that will promote and impact healthy human development including prevention, intervention and care also among people in vulnerable conditions. | ||
| 588 | |a Description based on publisher supplied metadata and other sources. | ||
| 590 | |a Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2023. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. | ||
| 650 | 0 | |a Substance abuse -- Treatment. | |
| 650 | 0 | |a Teenagers -- Substance use. | |
| 650 | 0 | |a Young adults -- Substance use. | |
| 655 | 4 | |a Electronic books. | |
| 700 | 1 | |a Kaplan, Gabriel. | |
| 700 | 1 | |a Patel, Dilip R. | |
| 700 | 1 | |a Merrick, Joav. | |
| 776 | 0 | 8 | |i Print version: |a Greydanus, Donald E. |t Substance Abuse in Adolescents and Young Adults |d Berlin/Boston : De Gruyter, Inc.,c2013 |z 9783110313017 |
| 797 | 2 | |a ProQuest (Firm) | |
| 830 | 0 | |a Health, Medicine and Human Development Ser. | |
| 856 | 4 | 0 | |u https://ebookcentral.proquest.com/lib/suleyman-ebooks/detail.action?docID=1209368 |z Click to View |